首页> 外文期刊>Cancer Communications >Liquid biopsy for esophageal cancer: Is detection of circulating cell-free DNA as a biomarker feasible?
【24h】

Liquid biopsy for esophageal cancer: Is detection of circulating cell-free DNA as a biomarker feasible?

机译:食管癌的液体活检:检测循环无细胞DNA作为生物标志物可行的吗?

获取原文
获取外文期刊封面目录资料

摘要

Esophageal cancer (EC) is a common cancer and is histopathologically classified into esophageal squamous cell carcinoma and esophageal adenocarcinoma. EC is a worldwide public health issue because of late diagnosis and lack of effective therapy. In contrast to standard tumor biopsies, liquid biopsies are emerging as a tool which is minimally invasive that can complement or even substitute more classical approaches. Specifically, cell-free DNA (cfDNA) has shown promise in cancer-related clinical applications. Indeed, cfDNA has been shown to be an effective circulating biomarker for non-invasive cancer diagnosis and monitoring of cancer patients. Although the clinical application of cfDNA has been reported on other cancers, few studies have evaluated its use in EC. Here, we review this relevant literature and discuss limitations and advantages of its application in the diagnosis and monitoring of EC.
机译:食管癌(EC)是一种常见的癌症,是组织病理学上分类为食管鳞状细胞癌和食道腺癌。 由于延迟诊断和缺乏有效治疗,EC是全球公共卫生问题。 与标准肿瘤活组织检查相反,液体活组织检查是浇铸作为更微小的侵入性的工具,其可以补充或甚至代替更古典方法。 具体地,无细胞DNA(CFDNA)在癌症相关的临床应用中显示出许可。 实际上,CFDNA已被证明是用于非侵入性癌症诊断和癌症患者的监测的有效循环生物标志物。 虽然CFDNA的临床应用已经报告了其他癌症,但很少有研究评估其在EC中的使用。 在这里,我们回顾了这一相关文献,并讨论了其在EC诊断和监测中应用的局限性和优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号